Semaglutide

Semaglutide is a synthetic analog of human GLP-1 (glucagon-like peptide-1) with 94% structural homology to the native hormone. GLP-1 is an incretin hormone secreted by intestinal L-cells in response to food intake. Its natural half-life is only 1-2 minutes because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Semaglutide's molecular modifications — an amino acid substitution at position 8 (Aib replacing Ala) to resist DPP-4 cleavage, plus a C-18 fatty di-acid spacer that binds to serum albumin — extend its functional half-life to approximately 165 hours (7 days).

The primary weight loss mechanism is central appetite suppression. GLP-1 receptors are densely expressed in the hypothalamus (arcuate nucleus and paraventricular nucleus) and the brainstem (nucleus tractus solitarius and area postrema). Semaglutide activates these receptors to reduce hunger signals, increase satiety, and decrease the reward value of food. Brain imaging studies (fMRI) have shown that semaglutide reduces activation of brain regions associated with food craving and reward processing when subjects are shown images of high-calorie foods.

Peripheral mechanisms complement the central appetite effects. Semaglutide slows gastric emptying by 10-30%, causing food to remain in the stomach longer and prolonging post-meal fullness. It stimulates glucose-dependent insulin secretion from pancreatic beta cells (only when blood glucose is elevated, reducing hypoglycemia risk). It suppresses glucagon secretion from alpha cells, reducing hepatic glucose output. It also has direct cardiovascular benefits — the SUSTAIN-6 and SELECT trials demonstrated reduced rates of major adverse cardiovascular events (MACE) including heart attack, stroke, and cardiovascular death.

An emerging area of research is semaglutide's potential neurological effects. GLP-1 receptors are present throughout the brain, and preclinical evidence suggests neuroprotective properties. Clinical trials are underway investigating semaglutide for Alzheimer's disease (EVOKE trial), Parkinson's disease, and alcohol use disorder — conditions where the central GLP-1 receptor activation may provide therapeutic benefit independent of weight loss.

The STEP (Semaglutide Treatment Effect in People with obesity) trial program is the most extensive clinical development program for any weight loss drug in history. STEP 1 (n=1,961) demonstrated 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4mg vs 2.4% with placebo. 86.4% of semaglutide patients achieved ≥5% weight loss, and 32.0% achieved ≥20% weight loss. These results were published in the New England Journal of Medicine in February 2021.

STEP 2 (n=1,210) studied semaglutide specifically in patients with type 2 diabetes, showing 9.6% mean weight loss — less than STEP 1 because diabetes medications and metabolic dysregulation can attenuate weight loss response. STEP 3 (n=611) combined semaglutide with intensive behavioral therapy and showed 16.0% mean weight loss. STEP 4 (n=902) was a withdrawal study demonstrating that patients who stopped semaglutide after 20 weeks regained approximately two-thirds of lost weight within 48 weeks — establishing that continuous treatment is necessary to maintain weight loss.

STEP 5 (n=304) extended the treatment duration to 104 weeks (2 years) and showed sustained 15.2% mean weight loss, confirming long-term efficacy. STEP 8 compared semaglutide 2.4mg directly against liraglutide 3.0mg (Saxenda) and demonstrated semaglutide's clear superiority: 15.8% vs 6.4% mean weight loss at 68 weeks.

The SELECT trial (n=17,604) was a landmark cardiovascular outcomes trial studying semaglutide 2.4mg in overweight/obese patients without diabetes but with established cardiovascular disease. Published in November 2023 in the New England Journal of Medicine, SELECT showed a 20% reduction in MACE (major adverse cardiovascular events: cardiovascular death, non-fatal heart attack, non-fatal stroke). This was the first time a weight loss drug demonstrated cardiovascular mortality benefit in a dedicated outcomes trial.

In body composition analysis, approximately 60-65% of weight lost on semaglutide is fat mass and 35-40% is lean mass (muscle + bone). This lean mass loss is clinically significant and is the primary reason resistance training is strongly recommended for all patients on GLP-1 therapy. Adequate protein intake (1.6-2.2g/kg body weight) also helps preserve lean mass during rapid weight loss.

Semaglutide for weight management (Wegovy) follows a mandatory dose escalation schedule designed to minimize gastrointestinal side effects. The escalation: Weeks 1-4: 0.25mg/week → Weeks 5-8: 0.5mg/week → Weeks 9-12: 1.0mg/week → Weeks 13-16: 1.7mg/week → Week 17+: 2.4mg/week (maintenance). Patients who cannot tolerate a dose increase should remain at the current dose for an additional 4 weeks before re-attempting escalation.

For type 2 diabetes (Ozempic), the dosing is lower: starting at 0.25mg/week for 4 weeks, then 0.5mg/week, with optional escalation to 1.0mg or 2.0mg/week based on glycemic response. The diabetes dosing does not reach the 2.4mg weight management dose.

The oral formulation (Rybelsus) uses semaglutide co-formulated with the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate). SNAC creates a localized pH elevation in the stomach that protects semaglutide from pepsin degradation and promotes transient absorption across the gastric epithelium. Oral bioavailability is approximately 0.4-1% — extremely low, which is why the oral dose (14mg daily) is much higher than the injectable dose (2.4mg weekly). Oral semaglutide must be taken on an empty stomach with no more than 4 oz of water, and patients must wait at least 30 minutes before eating or drinking anything else.

In the research peptide context, semaglutide is typically supplied as a lyophilized powder in vials of 2-5mg. Reconstitution with bacteriostatic water follows the same principles as other peptides. Research protocols often follow the same dose escalation as the FDA-approved label, starting at lower doses and increasing gradually to assess individual tolerance before reaching maintenance doses.

Gastrointestinal side effects are the dominant adverse events and affect the majority of patients. In STEP 1: nausea 44.2% (vs 16.0% placebo), diarrhea 29.7% (vs 15.9%), vomiting 24.8% (vs 6.8%), constipation 24.2% (vs 11.1%), and abdominal pain 22.0% (vs 10.0%). These effects are dose-dependent, peak during the escalation phase (weeks 4-12), and typically improve over time as the body adapts. The dose escalation schedule specifically targets minimizing these effects.

Serious but rare adverse events include: acute pancreatitis (reported in <1% of clinical trial participants, though the causal relationship is not definitively established), gallbladder disease (cholelithiasis and cholecystitis — driven by rapid weight loss rather than the drug itself), and injection site reactions (minor, infrequent). A black box warning exists for thyroid C-cell tumors based on rodent studies showing medullary thyroid carcinoma at high doses. This has NOT been observed in human clinical trials through 5+ years of follow-up data. Semaglutide is absolutely contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2).

The weight regain phenomenon is well-documented. STEP 4 showed that patients who stopped semaglutide after 20 weeks of treatment regained approximately two-thirds of the weight they had lost within 48 weeks. This establishes semaglutide as a chronic therapy for most patients, similar to blood pressure or cholesterol medications — the condition returns when treatment stops. This has significant implications for treatment planning and expectations.

Lean mass loss (muscle + bone) represents approximately 35-40% of total weight lost. For patients losing 15-20% of body weight, this means 5-8% lean mass reduction. This is clinically significant and can lead to sarcopenia (muscle wasting) in older patients. Concurrent resistance training (minimum 3x/week) and high protein intake (1.6-2.2g/kg lean body mass) are considered essential adjuncts to semaglutide therapy. Some research protocols add growth hormone peptides (CJC-1295 + Ipamorelin) alongside semaglutide to counteract muscle catabolism, though this combination has not been studied in clinical trials.